1Revuz J, Guillaume JC, Janier M, et al. Crossover study of thalidomide vs placebo in severe recurrent aphthous stomatitis. Arch Dermatol, 1990, 126: 923-927.
2Buno IJ, Huff JC, Weston WL, et al. Elevated levels of interferon gamma, tumor necrosis factor alpha, interleukins 2, 4, and 5, but not interleukin 10, are present in recurrent aphthous stomatitis. Arch Dermatol, 1998,134: 827-831.
3Eisen D, Lynch DP. Selecting topical and systemic agents for recurrent aphthous stomatitis. Cutis, 2001,68: 201-206.
4Nasca MR, O'Toole EA, Palicharla P, et al. Thalidomide increases human keratinocyte migration and proliferation. J Invest Dermatol, 1999, 113: 720-724.
5Hamuryudan V, Mat C, Saip S, et al. Thalidomide in the treatment of the mucocutaneous lesions of Behcet syndrome. A randomized, double-blind, placebo controlled trial. Ann Intern Med, 1998,128: 443-459.
6Kari JA, Shah V, Dillon MJ. Behcet's disease in UK children: clinical features and treatment including thalidomide. Rheumatology(Oxford), 2001,40: 933-938.
7Macario-Barrel A, Balguerie X, Joly P. Treatment of erosive oral lichen planus with thalidomide. Ann Dermatol Venereol, 2003,130(12 Pt 1): 1109-1112.
8Knop J, Bonsmann G, Happle R, et al. Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus. Br J Dermatol, 1983,108:461-466.
9Alfadley A, Al-Rayes H, Hussein W, et al. Thalidomide for treatment of severe generalized discoid lupus lesions in two patients with systemic lupus erythematosus. J Am Acad Dermatol, 2003,48(5 Suppl): S89-91.
10Kyriakis KP, Kontochristopoulos GJ, Panteleos DN. Experience with low-dose thalidomide therapy in chronic discoid lupus erythematosus. Int J Dermatol, 2000, 39: 218-222.
